查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922951

女性用事後緊急避孕藥市場依活性成分、劑型、給藥途徑、銷售管道及最終用戶分類－2026年至2032年全球預測

Female Emergency Contraceptive Pill Market by Active Ingredient, Dosage Form, Dose Regimen, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，女性用事後緊急避孕藥市場價值將達到 6.5321 億美元，到 2026 年將成長至 7.0046 億美元，到 2032 年將達到 11.8344 億美元，複合年成長率為 8.86%。

主要市場統計數據
基準年 2025 6.5321億美元
預計年份：2026年 7.046億美元
預測年份：2032年 11.8344億美元
複合年成長率 (%) 8.86%

這是一部權威的導論，全面回顧了影響現代醫療保健中女性用事後緊急避孕藥的臨床、監管、分銷和人口統計因素。

女性用事後緊急避孕藥領域正處於戰略十字路口，臨床創新、監管細則和不斷變化的獲取模式在此交會。本導言旨在幫助讀者理解產品層面的差異、分銷系統和消費者群體特徵如何共同影響商業性和公共衛生結果。透過圍繞活性成分、獲取管道、人口需求促進因素、劑型和不斷變化的政策展開討論，以下分析為制定有針對性的戰略應對措施奠定了基礎。

監管現代化、數位醫療整合和供應鏈創新將如何共同重塑事後緊急避孕藥的取得管道和商業策略

在政策現代化、數位醫療融合以及消費者期望不斷變化等因素的推動下，事後緊急避孕藥的研發、取得和配方方式發生了變革性轉變。首先，監管政策的調整擴大了許多地區的網路基地台，迫使藥局和遠端醫療服務提供者重新設計服務模式，以實現當日取藥和線上購買。其次，產品配方和臨床證據的進步改變了臨床醫生和消費者評估各種方案的方式，更加重視易用性、藥效持續時間和副作用情況。第三，供應鏈創新和無需低溫運輸的配送方式減少了物流摩擦，加快了關鍵網路基地台的補貨速度，並提高了庫存可靠性。

評估2025年美國關稅措施及其對整個價值鏈的採購、供應多元化、庫存管理和定價實踐的影響

2025年實施的關稅和貿易政策調整，為依賴國際採購的活性藥物成分和製劑產品的供應鏈管理、採購和定價動態帶來了新的複雜性。關稅調整加劇了依賴跨境採購的製造商和經銷商的成本敏感性，促使他們即時採取多項營運措施以保障利潤，包括供應商多元化、關鍵原料近岸採購以及重新談判長期合約。同時，採購團隊加快了多家供應商和採購管道的資格審核，以降低海關延誤和合規成本上升帶來的前置作業時間風險。

深入分析策略重點與原料藥屬性、給藥途徑、目標族群、銷售管道和劑型偏好之間的關聯。

詳細的細分分析揭示了活性成分、銷售管道、終端用戶群體、銷售管道和劑型等方面的獨特商業和臨床特徵，這些特徵共同決定了產品的定位和部署優先順序。以活性成分分類的市場研究包括levonorgestrel（評估劑量分別為 0.75 毫克和 1.5 毫克）、米非司酮（10 毫克）和醋酸烏利司他（30 毫克）。每種活性成分的療效、適應症和監管過程均不相同，這會影響標籤、諮詢要求和競爭分析。依銷售管道分類，非處方藥與處方箋的取得限制直接影響消費者的購買管道、藥劑師的職責和銷售點教育需求，進而影響製造商的互動策略。

美洲、歐洲、中東和非洲以及亞太地區的區域監管差異、分銷能力和文化期望如何影響差異化的市場准入和商業化方法？

區域趨勢對法規結構、分銷基礎設施和消費者預期產生了深遠影響，導致美洲、歐洲、中東和非洲地區以及亞太地區的市場行為存在差異。在美洲，監管現代化和遠端醫療的普及增加了網路基地台，同時也鼓勵藥局主導相關舉措，以確保及時供應。支付方結構和公共衛生宣傳活動也在影響介入措施融入更廣泛的生殖健康服務的程度。歐洲、中東和非洲地區的情況則更為多樣化，一些地區強調嚴格的臨床通訊協定和配藥控制，而其他地區則轉向更自由的取得模式。因此，監管機構的應對措施以及與當地相關人員的溝通是成功實施的關鍵。

競爭格局分析揭示了現有經銷商、靈活的學名藥和數位化優先的分銷商如何融合，從而重新定義藥品獲取、可靠性和通路創新。

女性事後緊急避孕藥市場的競爭格局由老牌製藥公司、專業生殖健康產品製造商和數位化原生經銷商組成，它們都在重新定義產品的覆蓋範圍和便利性。老牌製藥公司繼續利用其深厚的監管專業知識、廣泛的生產基地以及與機構負責人建立的長期合作關係，以維持其產品在商店的佔有率和臨床醫生的信任。同時，利基市場和非專利製造商專注於成本效益高的配方和靈活的營運模式，使其能夠快速應對因採購趨勢和關稅變化而導致的供應中斷。數位化優先的新興參與企業和線上藥局透過便利、快速和私密的配送模式，加速了消費者對緊急避孕藥的接受度，從而改變了傳統零售的動態。

這是一份實用的策略指南，旨在幫助領導者整合監管合規、供應商多元化、高階需求預測和通路特定商業化，從而增強企業韌性並實現成長。

產業領導者應採取多管齊下的策略，平衡監管合規、供應鏈韌性和以消費者為中心的配送，以掌握機會並管控風險。首先，應積極主動地與監管機構和支付方溝通，預測政策變化，並在有證據支持的情況下，簡化非處方藥過渡和擴大用藥管道。其次，應實現供應商網路多元化，並對區域契約製造進行認證，以最大限度地減少關稅相關干擾，並縮短前置作業時間。同時，應部署先進的需求預測工具，在不影響服務水準的前提下最佳化庫存。

一項綜合性的混合方法研究設計，結合了關鍵相關人員訪談、監管資訊綜合、供應鏈圖譜繪製和情境分析，以得出檢驗的策略見解。

本研究採用混合方法，將一手質性研究與二手證據綜合相結合，以確保研究結果的可靠檢驗。一手研究包括對關鍵行業專家、藥劑師、監管專家和分銷經理進行結構化訪談，以收集有關藥品獲取、配製行為和運營挑戰的實證見解。這些定性見解與二手監管文件、臨床文獻和公共公告相結合，以闡明觀察到的模式並檢驗新出現的主題。

整合監管情報、供應鏈韌性和管道特定參與以維持事後緊急避孕藥的可及性和公共衛生結果的概要

總之，女性用事後緊急避孕藥格局正受到不斷變化的監管法規、供應鏈重組以及消費者獲取偏好轉變等因素的共同影響而重塑。能夠預見政策趨勢、建立穩健的籌資策略並針對合適的銷售管道進行行銷活動的相關人員將獲得決定性優勢。透過活性成分或劑型進行產品差異化，並結合針對特定年齡層的精準推廣和合理的銷售管道組合，可以更有效地將臨床療效與使用者需求相匹配。此外，區域差異也需要製定符合法規環境和文化期望的在地化策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 銷售管道分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章女性用事後緊急避孕藥市場（依活性成分分類）

  • levonorgestrel
  • 醋酸烏利司他
  • 米非司酮

第9章女性用事後緊急避孕藥市場（以劑型分類）

  • 凝膠
  • 藥片

第10章女性用事後緊急避孕藥市場（依給藥途徑分類）

  • 單一劑量
    • 標準管理期間
    • 延長行政期間
  • 分次服用
    • 12小時間隔
    • 24小時間隔

第11章女性用事後緊急避孕藥市場銷售管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章女性用事後緊急避孕藥市場（依最終用戶分類）

  • 青少年
    • 15-17歲
    • 18-19歲
  • 年輕人
    • 20-24歲
    • 25-29歲
  • 成人
    • 30-34歲
    • 35歲或以上

第13章女性用事後緊急避孕藥市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章女性用事後緊急避孕藥市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國女性用事後緊急避孕藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國女性用事後緊急避孕藥市場

第17章：中國女性用事後緊急避孕藥市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Afaxys Pharma LLC
  • Apotex Inc.
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Foundation Consumer Healthcare LLC
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals Limited
  • HLL Lifecare Limited
  • Laboratoire HRA Pharma SAS
  • Lupin Limited
  • Mankind Pharma Limited
  • Organon & Co.
  • Perrigo Company plc
  • Pfizer Inc.
  • Piramal Enterprises Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-867BED9A9E7A

The Female Emergency Contraceptive Pill Market was valued at USD 653.21 million in 2025 and is projected to grow to USD 700.46 million in 2026, with a CAGR of 8.86%, reaching USD 1,183.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 653.21 million
Estimated Year [2026] USD 700.46 million
Forecast Year [2032] USD 1,183.44 million
CAGR (%) 8.86%

An authoritative introduction framing clinical, regulatory, distributional, and demographic forces shaping the female emergency contraceptive landscape in contemporary healthcare

The female emergency contraceptive landscape sits at a strategic crossroads where clinical innovation, regulatory nuance, and shifting access paradigms converge. This introduction positions the reader to appreciate how product-level differences, distribution frameworks, and consumer demographics collectively shape commercial and public-health outcomes. By framing the discussion around active ingredients, channels of access, demographic demand drivers, dosage formats, and evolving policy, the following analysis establishes context for targeted strategic response.

Across therapeutic modalities, differences in mechanism of action, dosing regimens, and regulatory classifications have meaningful implications for prescribing practices, over-the-counter availability, and consumer choice. As regulatory agencies reconcile competing evidence streams and jurisdictions adapt their pharmacy and telehealth rules, stakeholders must anticipate both near-term operational impacts and longer-term shifts in demand elasticity. This introduction prepares commercial and clinical leaders to interpret subsequent sections, which delve into transformative market shifts, the 2025 U.S. tariff environment, granular segmentation insights, and regionally differentiated considerations that collectively inform robust go-to-market strategies.

How regulatory modernization, digital health integration, and supply-chain innovation collectively recalibrate access pathways and commercial strategies for emergency contraceptives

Transformative shifts are reshaping how female emergency contraceptives are developed, accessed, and prescribed, driven by policy modernization, digital health integration, and evolving consumer expectations. First, regulatory adaptations have expanded points of access in many settings, prompting pharmacies and telehealth providers to redesign service models to accommodate same-day access and online fulfillment. Second, advances in product formulations and comparative clinical evidence have altered how clinicians and consumers evaluate options, emphasizing ease of use, efficacy windows, and side effect profiles. Third, supply chain innovations and cold-chain-independent distribution have reduced logistical friction, enabling faster replenishment and more reliable stock at critical access points.

Consequently, commercial strategies have shifted from broad-based promotional tactics toward more targeted, education-centric outreach that addresses both healthcare professional decision-making and consumer awareness. These shifts are amplified by digital engagement channels that allow for precise segmentation and rapid feedback loops, enabling iterative refinement of messaging and service design. Taken together, the landscape now rewards organizations that integrate regulatory foresight, product differentiation, and customer-centric channel orchestration to capture sustainable value.

Assessment of the 2025 U.S. tariff interventions and how they reshaped procurement, supplier diversification, inventory posture, and pricing approaches across the value chain

The imposition of tariffs and trade-policy shifts in 2025 introduced a new layer of complexity to supply-chain management, procurement, and pricing dynamics for products that rely on internationally sourced active pharmaceutical ingredients and finished doses. Tariff adjustments increased the cost sensitivity of manufacturers and distributors who rely on cross-border procurement, prompting several immediate operational responses including supplier diversification, nearshoring of critical inputs, and renegotiation of long-term contracts to protect margin integrity. In parallel, procurement teams accelerated efforts to qualify multiple suppliers and routings to mitigate lead-time risk arising from customs delays and elevated compliance costs.

Beyond direct cost impacts, the tariff environment has influenced strategic decisions about inventory posture and channel pricing. Organizations reassessed safety-stock policies and invested in predictive demand analytics to balance service levels with capital efficiency. Some manufacturers prioritized contractual commitments with national distributors to secure shelf presence despite incremental landed costs, while others pursued cooperative purchasing or consortia arrangements to share tariff-related burdens. Importantly, the tariff-driven recalibration varied by product attributes: formulations with narrow supplier bases or specialized manufacturing steps faced steeper operational strain than widely produced tablet formulations. Ultimately, the 2025 tariff landscape reinforced the importance of supply-chain resilience as a core competency, compelling firms to align procurement, regulatory, and commercial planning more tightly than before.

In-depth segmentation-driven analysis linking active ingredient nuances, access modalities, demographic cohorts, sales channels, and dosage form preferences to strategic priorities

A nuanced segmentation lens reveals diverse commercial and clinical dynamics across active ingredient, distribution channel, end-user age group, sales channel, and dosage form that together determine product positioning and outreach priorities. Based on Active Ingredient, market studies differentiate Levonorgestrel, which is assessed at both 0.75 mg and 1.5 mg dosages; Mifepristone, represented at 10 mg; and Ulipristal Acetate, evaluated at 30 mg. Each active ingredient carries distinct efficacy profiles, windows of use, and regulatory histories that influence labeling, counseling requirements, and competitive narrative. Based on Distribution Channel, distinctions between Over The Counter availability and Prescription-only access directly affect consumer pathways, pharmacist obligations, and point-of-sale educational needs, thus shaping manufacturer engagement strategies.

Based on End User Age Group, analysis spans age cohorts 15-19, 20-24, 25-29, 30-34, and 35+, illuminating how life stage, reproductive intentions, and health-service utilization patterns drive heterogeneous demand. Younger cohorts often demonstrate higher sensitivity to privacy and convenience, elevating the importance of discreet channels and digital touchpoints, whereas older cohorts may engage more directly with clinical providers. Based on Sales Channel, the differentiation among Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy underscores the operational and regulatory nuances of institutional procurement, e-commerce fulfillment, and point-of-sale counseling. Finally, based on Dosage Form, the presence of Gel and Tablet formats highlights formulation preferences, adherence considerations, and manufacturing complexity. Together, these segmentation lenses inform targeted clinical communication, channel-tailored promotions, and supply-chain planning to optimize access across population segments.

How regional regulatory diversity, distribution capabilities, and cultural expectations across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated access and commercialization approaches

Regional dynamics exert a powerful influence on regulatory frameworks, distribution infrastructure, and consumer expectations, leading to differentiated market behaviors across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory modernization and telehealth expansion have increased points of access while stimulating pharmacy-led initiatives to support timely availability; payer structures and public-health campaigns also influence the degree to which interventions are integrated into broader reproductive-health services. Moving to Europe, Middle East & Africa, heterogeneity is pronounced: some jurisdictions emphasize tight clinical protocols and prescription controls, while others have moved toward more liberalized access models; consequently, regulatory navigation and localized stakeholder engagement remain essential for successful rollout.

The Asia-Pacific region presents a mix of urbanized markets with advanced e-commerce ecosystems and jurisdictions where supply-chain constraints and varying regulatory timelines necessitate bespoke commercialization approaches. Across all regions, differences in cultural norms, health-system financing, and pharmacy practice drive distinct expectations for counseling, packaging, and labeling. Therefore, global strategic planning must accommodate regional regulatory frameworks, channel readiness, and demographic demand vectors in order to effectively prioritize investments and localization efforts.

Competitive landscape analysis revealing how legacy manufacturers, agile generic producers, and digital-first distributors converge to redefine access, credibility, and channel innovation

Competitive dynamics in the female emergency contraceptive space reflect a mix of legacy pharmaceutical players, specialized reproductive-health manufacturers, and digitally native distributors that are redefining reach and convenience. Established pharmaceutical companies continue to leverage deep regulatory expertise, broad manufacturing footprints, and long-standing relationships with institutional buyers to maintain shelf presence and clinician trust. At the same time, niche manufacturers and generic producers focus on cost-efficient formulations and agility, enabling faster responses to procurement shifts and tariff-induced supply interruptions. Digital-first entrants and online pharmacies are accelerating consumer adoption through convenience, rapid delivery, and discreet fulfillment models, altering conventional retail dynamics.

These competing forces create opportunities for strategic partnerships, co-marketing arrangements, and distribution agreements that bridge institutional credibility with digital reach. Moreover, intellectual-property considerations, manufacturing specialization for specific dosage forms, and regulatory dossiers for varying active ingredients differentiate competitive positioning. Firms that combine clinical credibility, manufacturing resilience, and channel innovation will be best positioned to capture long-term demand while navigating pricing pressures and regulatory scrutiny.

Actionable strategic playbook for leaders to synchronize regulatory engagement, supplier diversification, advanced forecasting, and channel-specific commercialization to build resilience and growth

Industry leaders should adopt a multi-pronged strategy that balances regulatory engagement, supply-chain resilience, and consumer-centric distribution to capture opportunity while managing risk. First, invest in proactive regulatory and payer engagement to anticipate policy shifts and to streamline pathways for over-the-counter transitions or expanded access where evidence supports them. Second, diversify supplier networks and qualify regional contract manufacturers to minimize exposure to tariff-related disruption and to shorten lead times, while implementing advanced demand-forecasting tools to optimize inventory without compromising service levels.

Third, prioritize channel-tailored commercialization: enhance pharmacist-facing education and point-of-sale counseling for over-the-counter channels, while building seamless telehealth and e-commerce integrations to meet privacy-sensitive cohorts. Fourth, refine product portfolios by aligning active ingredient positioning and dosage-form offerings with distinct end-user cohorts to maximize clinical appropriateness and market relevance. Finally, pursue strategic partnerships that combine distribution scale with digital capabilities to expand reach and improve the end-user experience. Taken together, these actions will strengthen market responsiveness, preserve margin integrity, and support sustained access.

Comprehensive mixed-methods research design integrating primary stakeholder interviews, regulatory synthesis, supply-chain mapping, and scenario analysis to produce validated strategic insights

This research employs a mixed-methods approach that integrates primary qualitative inquiry with secondary evidence synthesis to ensure robust, triangulated insights. Primary research included structured interviews with key opinion leaders, pharmacists, regulatory specialists, and distribution managers to capture experiential knowledge about access, prescribing behavior, and operational challenges. These qualitative inputs were synthesized with secondary regulatory documentation, clinical literature, and public policy announcements to contextualize observed patterns and to validate emergent themes.

Analytical methods combined thematic analysis of interview transcripts with cross-sectional assessment of distribution channel behaviors and supplier network configurations. Where relevant, scenario planning workshops informed sensitivity testing of tariff and regulatory contingencies, while supply-chain mapping exercises identified critical nodes and single-source risk factors. Throughout, the methodology emphasized corroboration across data sources and transparency in assumptions to support actionable insights for stakeholders seeking to align clinical considerations, commercial objectives, and operational execution.

Concluding synthesis on aligning regulatory intelligence, supply-chain resilience, and channel-tailored engagement to sustain access and public-health outcomes in emergency contraception

In conclusion, the female emergency contraceptive landscape is being reshaped by a confluence of regulatory evolution, supply-chain recalibration, and shifting consumer access preferences. Stakeholders that anticipate policy movement, build resilient procurement strategies, and tailor channel-appropriate engagement will gain a decisive advantage. Product differentiation across active ingredients and dosage forms, when combined with targeted outreach to distinct age cohorts and the right sales-channel mix, enables more effective matching of clinical benefit to user needs. Additionally, regional variations necessitate localized strategies that respect regulatory context and cultural expectations.

As a result, decision-makers should prioritize investments that strengthen regulatory intelligence, supplier flexibility, and digital distribution capabilities. By doing so, organizations can both safeguard continuity of supply in the face of trade and tariff pressures and create more responsive pathways to reach consumers who require timely access to emergency contraception. The strategic imperative is clear: align clinical evidence, channel design, and operational resilience to sustain access and to support public-health objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Female Emergency Contraceptive Pill Market, by Active Ingredient

  • 8.1. Levonorgestrel
  • 8.2. Ulipristal Acetate
  • 8.3. Mifepristone

9. Female Emergency Contraceptive Pill Market, by Dosage Form

  • 9.1. Gel
  • 9.2. Tablet

10. Female Emergency Contraceptive Pill Market, by Dose Regimen

  • 10.1. Single Dose
    • 10.1.1. Standard Window
    • 10.1.2. Extended Window
  • 10.2. Split Dose
    • 10.2.1. 12 Hour Interval
    • 10.2.2. 24 Hour Interval

11. Female Emergency Contraceptive Pill Market, by Sales Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Female Emergency Contraceptive Pill Market, by End User

  • 12.1. Adolescents
    • 12.1.1. 15 To 17 Years
    • 12.1.2. 18 To 19 Years
  • 12.2. Young Adults
    • 12.2.1. 20 To 24 Years
    • 12.2.2. 25 To 29 Years
  • 12.3. Adults
    • 12.3.1. 30 To 34 Years
    • 12.3.2. 35 Years And Above

13. Female Emergency Contraceptive Pill Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Female Emergency Contraceptive Pill Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Female Emergency Contraceptive Pill Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Female Emergency Contraceptive Pill Market

17. China Female Emergency Contraceptive Pill Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Afaxys Pharma LLC
  • 18.6. Apotex Inc.
  • 18.7. Bayer AG
  • 18.8. Cipla Limited
  • 18.9. Dr. Reddy's Laboratories Ltd.
  • 18.10. Foundation Consumer Healthcare LLC
  • 18.11. Gedeon Richter Plc.
  • 18.12. Glenmark Pharmaceuticals Limited
  • 18.13. HLL Lifecare Limited
  • 18.14. Laboratoire HRA Pharma SAS
  • 18.15. Lupin Limited
  • 18.16. Mankind Pharma Limited
  • 18.17. Organon & Co.
  • 18.18. Perrigo Company plc
  • 18.19. Pfizer Inc.
  • 18.20. Piramal Enterprises Limited
  • 18.21. Sandoz International GmbH
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY LEVONORGESTREL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ULIPRISTAL ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY MIFEPRISTONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STANDARD WINDOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STANDARD WINDOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY STANDARD WINDOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY EXTENDED WINDOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY EXTENDED WINDOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY EXTENDED WINDOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 12 HOUR INTERVAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 12 HOUR INTERVAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 12 HOUR INTERVAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 24 HOUR INTERVAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 24 HOUR INTERVAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 24 HOUR INTERVAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 15 TO 17 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 15 TO 17 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 15 TO 17 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 18 TO 19 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 18 TO 19 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 18 TO 19 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 20 TO 24 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 20 TO 24 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 20 TO 24 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 25 TO 29 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 25 TO 29 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 25 TO 29 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30 TO 34 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30 TO 34 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 30 TO 34 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 35 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 35 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY 35 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 184. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 185. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 186. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 217. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 218. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 219. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 228. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 229. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 230. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SINGLE DOSE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SPLIT DOSE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADOLESCENTS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY YOUNG ADULTS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA FEMALE EMERGENCY CONTRACEPTIVE PILL MARKET SIZE, BY ADULTS, 2018-2032 (USD MILLION)